CureVac

CureVac GmbH is a biopharmaceutical company specializing in the prophylactic and therapeutic application of messenger RNA (mRNA). CureVac's lead programme is dedicated to the development of active immunotherapies (based on its RNActiveÂ® technology) for the treatment of prostate cancer and non-small cell lung cancer. Furthermore, in preclinical studies, CureVac is developing prophylactic vaccines and adjuvants to address infectious diseases.

Company Growth (employees)

Type

Private

Tübingen, DE

Founded

2000

Size (employees)

126 (est)+2%

Website

curevac.com

CureVac was founded in 2000 and is headquartered in Tübingen, DE

Key People at CureVac

Ingmar Hoerr

Chief Executive Officer

Mathias Hothum

Baord of Directors

Franz-Werner Haas

Chief Corporate Officer

Ulrike Gnad-Vogt

Acting Chief Medical Officer

Mariola Fotin-Mleczek

Acting Chief Scientific Officer

Christof Hettich

Baord of Directors

CureVac Office Locations

CureVac has an office in Tübingen

Tübingen, DE (HQ)

Paul Ehrlich Str. 15

CureVac Metrics

Summary Metrics

Founding Date	2000
Total Funding	$387.3 m
Latest funding size	$29.5 m
Time since last funding	7 months
Investors	Baillie Gifford, DH Capital, Bill & Melinda Gates Foundation, OH Beteiligungen, dievini Hopp Biotech Holding, Baden-Württembergische Versorgungsanstalt für Ärzte, Chartwave, Coppel Family, Landeskreditbank Baden-Württemberg, LBBW Asset Management, Northview LifeSciences, Sigma Group

CureVac's latest funding round in November 2016 was reported to be $29.5 m. In total, CureVac has raised $387.3 m. CureVac's latest valuation is reported to be $1.7 b.